169 related articles for article (PubMed ID: 2388669)
1. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.
Bronspiegel-Weintrob N; Olivieri NF; Tyler B; Andrews DF; Freedman MH; Holland FJ
N Engl J Med; 1990 Sep; 323(11):713-9. PubMed ID: 2388669
[TBL] [Abstract][Full Text] [Related]
2. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
3. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M
J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155
[TBL] [Abstract][Full Text] [Related]
4. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
Wali YA; Taqi A; Deghaidi A
Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
[TBL] [Abstract][Full Text] [Related]
5. [Growth and endocrine function in major thalassemia].
Pérignon F; Brauner R; Souberbielle JC; de Montalembert M; Girot R
Arch Fr Pediatr; 1993 Oct; 50(8):657-63. PubMed ID: 8002739
[TBL] [Abstract][Full Text] [Related]
6. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major.
Moayeri H; Oloomi Z
Arch Iran Med; 2006 Oct; 9(4):329-34. PubMed ID: 17061604
[TBL] [Abstract][Full Text] [Related]
8. Short stature and truncal shortening in transfusion dependent thalassemia patients: results from a thalassemia center in Malaysia.
Hamidah A; Rahmah R; Azmi T; Aziz J; Jamal R
Southeast Asian J Trop Med Public Health; 2001 Sep; 32(3):625-30. PubMed ID: 11944728
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
Brittenham GM; Griffith PM; Nienhuis AW; McLaren CE; Young NS; Tucker EE; Allen CJ; Farrell DE; Harris JW
N Engl J Med; 1994 Sep; 331(9):567-73. PubMed ID: 8047080
[TBL] [Abstract][Full Text] [Related]
10. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.
Viprakasit V; Tanphaichitr VS; Mahasandana C; Assteerawatt A; Suwantol L; Veerakul G; Kankirawatana S; Pung-Amritt P; Suvatte V
J Med Assoc Thai; 2001 Jul; 84(7):929-41. PubMed ID: 11759973
[TBL] [Abstract][Full Text] [Related]
11. Low bone mineral density in adolescents with beta-thalassemia.
Vogiatzi MG; Autio KA; Mait JE; Schneider R; Lesser M; Giardina PJ
Ann N Y Acad Sci; 2005; 1054():462-6. PubMed ID: 16339698
[TBL] [Abstract][Full Text] [Related]
12. Growth velocity in transfusion dependent prepubertal thalassemia patients: results from a thalassemia center in Malaysia.
Hamidah A; Arini MI; Zarina AL; Zulkifli SZ; Jamal R
Southeast Asian J Trop Med Public Health; 2008 Sep; 39(5):900-5. PubMed ID: 19058587
[TBL] [Abstract][Full Text] [Related]
13. Survival in medically treated patients with homozygous beta-thalassemia.
Olivieri NF; Nathan DG; MacMillan JH; Wayne AS; Liu PP; McGee A; Martin M; Koren G; Cohen AR
N Engl J Med; 1994 Sep; 331(9):574-8. PubMed ID: 8047081
[TBL] [Abstract][Full Text] [Related]
14. [The mechanism of cataract formation in persons with beta-thalassemia].
Popescu C; Siganos D; Zanakis E; Padakis A
Oftalmologia; 1998; 45(4):10-3. PubMed ID: 10418622
[TBL] [Abstract][Full Text] [Related]
15. [Arrhythmia in thalassemia major: evaluation of iron chelating therapy by dynamic ECG].
Cavallaro L; Meo A; Busà G; Coglitore A; Sergi G; Satullo G; Donato A; Calabrò MP; Miceli M
Minerva Cardioangiol; 1993; 41(7-8):297-301. PubMed ID: 8233011
[TBL] [Abstract][Full Text] [Related]
16. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Wolfe L; Olivieri N; Sallan D; Colan S; Rose V; Propper R; Freedman MH; Nathan DG
N Engl J Med; 1985 Jun; 312(25):1600-3. PubMed ID: 4000198
[TBL] [Abstract][Full Text] [Related]
17. Growth and sexual development before and after sex steroid therapy in patients with thalassemia major.
Landau H; Gross V; Dagan I; Palti Z; Rachmilewitz EA; Spitz IM
Arch Intern Med; 1984 Dec; 144(12):2341-6. PubMed ID: 6439139
[TBL] [Abstract][Full Text] [Related]
18. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between growth disorders and iron overload in children with beta-thalassemia major].
Huang YL; Liu S; Xia T; Hao WG; Liang W; Sun X
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct; 10(5):603-6. PubMed ID: 18947480
[TBL] [Abstract][Full Text] [Related]
20. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
